Northern Mariana Islands
Hepatitis B
Download HBV dataPrevalence of chronic HBV (HBsAg+)
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 7.08 (5.89 - 8.14) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 7.88 (6.66 - 9.05) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.96 (6.69 - 9.31) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.93 (6.66 - 9.24) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.9 (6.59 - 9.35) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.85 (6.59 - 9.30) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.8 (6.57 - 9.22) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.76 (6.52 - 9.17) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.71 (6.46 - 9.28) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.66 (6.35 - 9.38) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.62 (6.39 - 9.18) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.58 (6.37 - 9.02) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.53 (6.32 - 8.88) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.47 (6.23 - 8.78) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.4 (6.11 - 8.68) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.31 (6.09 - 8.51) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.22 (6.03 - 8.39) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.14 (5.94 - 8.31) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.09 (5.90 - 8.27) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.06 (5.85 - 8.31) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.08 (5.92 - 8.31) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.15 (6.02 - 8.37) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.23 (6.11 - 8.43) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.29 (6.17 - 8.46) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.3 (6.16 - 8.46) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.28 (6.14 - 8.38) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.29 (6.07 - 8.38) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.3 (6.06 - 8.39) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.28 (5.99 - 8.36) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.23 (5.85 - 8.38) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.65 (6.37 - 8.76) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
Children under-5 years
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 2.55 (1.78 - 3.52) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 3.23 (2.27 - 4.46) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.25 (2.24 - 4.35) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.26 (2.22 - 4.35) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.24 (2.25 - 4.33) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.23 (2.24 - 4.31) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.23 (2.25 - 4.35) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.23 (2.22 - 4.33) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.21 (2.18 - 4.33) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.2 (2.14 - 4.32) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.19 (2.10 - 4.31) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.19 (2.13 - 4.25) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.2 (2.16 - 4.26) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.22 (2.21 - 4.29) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.24 (2.25 - 4.37) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.26 (2.23 - 4.43) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.24 (2.24 - 4.37) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.18 (2.20 - 4.24) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.1 (2.12 - 4.13) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.02 (2.05 - 4.08) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.99 (1.98 - 4.03) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.01 (2.02 - 4.05) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.07 (2.07 - 4.11) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.14 (2.11 - 4.24) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.2 (2.14 - 4.33) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.23 (2.15 - 4.36) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.22 (2.17 - 4.30) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.19 (2.17 - 4.22) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.16 (2.17 - 4.14) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.12 (2.16 - 4.08) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.09 (2.14 - 4.07) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
Number of people living with chronic HBV
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 3,010 (2,501 - 3,460) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 3,136 (2,614 - 3,593) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,298 (2,791 - 3,785) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,400 (2,849 - 3,978) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,459 (2,903 - 4,026) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,519 (2,931 - 4,167) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,576 (2,997 - 4,234) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,648 (3,066 - 4,315) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,742 (3,145 - 4,439) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,858 (3,224 - 4,639) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,987 (3,307 - 4,880) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,112 (3,449 - 4,966) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,212 (3,537 - 5,015) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,277 (3,593 - 5,046) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,318 (3,609 - 5,068) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,364 (3,582 - 5,119) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,441 (3,703 - 5,176) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,580 (3,824 - 5,316) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,781 (3,991 - 5,569) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,935 (4,113 - 5,776) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,874 (4,047 - 5,738) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,582 (3,841 - 5,388) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,208 (3,556 - 4,920) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,853 (3,252 - 4,482) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,565 (3,019 - 4,120) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,361 (2,842 - 3,898) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,271 (2,760 - 3,755) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,275 (2,737 - 3,744) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,305 (2,752 - 3,796) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,268 (2,688 - 3,750) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,106 (2,515 - 3,592) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
HBV-related death rate
National
Download| Value (per 100,000) | Year | Type | Source |
|---|---|---|---|
| 19 (15 - 23.50) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 11.14 (8.26 - 14.78) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 10.99 (8.19 - 14.31) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 10.62 (7.93 - 13.81) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 10.8 (8.07 - 13.98) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 10.52 (7.95 - 13.71) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 10.57 (8.08 - 13.63) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 10.55 (8.10 - 13.35) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 10.6 (8.10 - 13.56) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 10.36 (8.03 - 13.09) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 10.37 (8.12 - 13.03) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 10.08 (7.95 - 12.61) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 10.16 (7.99 - 12.73) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 10.14 (8.01 - 12.72) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 10.32 (8.18 - 12.91) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 10.56 (8.42 - 13.19) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 10.99 (8.76 - 13.64) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 11.66 (9.32 - 14.45) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 12.25 (9.77 - 15.13) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 12.8 (10.18 - 15.80) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 13.41 (10.72 - 16.49) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 14.04 (11.27 - 17.11) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 14.63 (11.81 - 17.82) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 15.54 (12.54 - 18.75) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 15.99 (12.92 - 19.32) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 15.1 (12.20 - 18.26) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 16.68 (13.45 - 20.19) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 17.56 (14.13 - 21.35) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 18.2 (14.47 - 22.09) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 18.64 (14.72 - 22.81) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 18.99 (15.02 - 23.48) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
HBV-related deaths
National
Download
Showing out of
Show more
Percent of liver cancer deaths attributable to HBV
National
Download
Showing out of
Show more
Number of needles/syringes per PWID per year
People who inject drugs (PWID)
Download| Value | Year | Type | Source |
|---|---|---|---|
| 0 (0 - 0) | 2016 | Survey/reported | Harm Reduction International, 2016 |
Percent of PWID accessing OST
People who inject drugs (PWID)
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 0 | 2016 | Survey/reported | Harm Reduction International, 2016 |
Eligible for HBV generic medicines
Eligible for HCV generic medicines
Hepatitis C
Download HCV dataPrevalence of chronic HCV (RNA+/cAg)
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 0.6 (0.49 - 0.72) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.59 (0.49 - 0.71) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.59 (0.48 - 0.71) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.59 (0.48 - 0.71) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.59 (0.48 - 0.71) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.59 (0.48 - 0.71) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.59 (0.48 - 0.71) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.59 (0.48 - 0.71) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.59 (0.48 - 0.71) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.59 (0.48 - 0.71) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.59 (0.48 - 0.71) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.59 (0.48 - 0.70) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.59 (0.47 - 0.70) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.58 (0.47 - 0.70) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.58 (0.47 - 0.69) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.58 (0.47 - 0.69) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.59 (0.48 - 0.71) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.6 (0.49 - 0.73) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.62 (0.50 - 0.75) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.62 (0.50 - 0.76) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.63 (0.51 - 0.76) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.63 (0.51 - 0.77) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.64 (0.51 - 0.77) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.64 (0.51 - 0.77) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.64 (0.51 - 0.77) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.64 (0.51 - 0.77) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.64 (0.51 - 0.77) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.64 (0.51 - 0.78) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.64 (0.51 - 0.78) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.63 (0.50 - 0.78) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.55 (0.45 - 0.68) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
Showing out of
Show more
Number of people living with chronic HCV (RNA+/cAg)
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 271 (216 - 334) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 286 (229 - 350) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 289 (232 - 352) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 286 (230 - 348) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 285 (230 - 347) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 293 (235 - 355) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 311 (251 - 376) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 339 (272 - 409) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 373 (299 - 451) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 408 (328 - 494) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 432 (349 - 526) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 429 (347 - 522) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 404 (326 - 486) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 374 (302 - 449) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 353 (284 - 424) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 342 (276 - 410) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 337 (271 - 403) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 333 (269 - 397) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 327 (265 - 392) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 318 (257 - 382) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 307 (249 - 372) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 296 (240 - 357) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 284 (232 - 342) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 274 (225 - 332) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 267 (218 - 322) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 261 (214 - 316) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 256 (211 - 309) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 252 (207 - 304) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 248 (205 - 299) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 245 (201 - 296) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 235 (189 - 288) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
Showing out of
Show more
HCV-related death rate
National
Download| Value (Deaths per 100,000) | Year | Type | Source |
|---|---|---|---|
| 7.78 (5.63 - 10.80) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 5.61 (3.93 - 7.96) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.54 (3.87 - 7.81) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.37 (3.80 - 7.50) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.45 (3.85 - 7.63) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.32 (3.81 - 7.32) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.35 (3.86 - 7.29) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.34 (3.82 - 7.36) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.11 (3.69 - 7.06) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.27 (3.79 - 7.31) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.89 (3.55 - 6.68) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.08 (3.67 - 7) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.73 (3.46 - 6.39) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.78 (3.49 - 6.48) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.73 (3.48 - 6.42) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.77 (3.49 - 6.51) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.16 (3.77 - 7.04) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.9 (3.58 - 6.68) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.35 (3.89 - 7.26) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.53 (4.06 - 7.47) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.72 (4.19 - 7.70) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.93 (4.33 - 7.95) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.13 (4.48 - 8.21) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.28 (4.61 - 8.44) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.43 (4.73 - 8.60) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.58 (4.87 - 8.91) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.84 (5.04 - 9.31) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.15 (5.22 - 9.67) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.41 (5.35 - 10.11) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.61 (5.49 - 10.46) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.78 (5.63 - 10.77) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
HCV-related deaths
National
Download
Showing out of
Show more
Percent of liver cancer deaths attributable to HCV
National
Download
Showing out of
Show more
Number of needles/syringes per PWID per year
People who inject drugs (PWID)
Download| Value | Year | Type | Source |
|---|---|---|---|
| 0 (0 - 0) | 2016 | Survey/reported | Harm Reduction International, 2016 |
Percent of PWID accessing OST
People who inject drugs (PWID)
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 0 | 2016 | Survey/reported | Harm Reduction International, 2016 |
Eligible for HBV generic medicines
Eligible for HCV generic medicines
Overview
Prevalence (national)
Modelled
Survey/surveillance
No data available
No data available
Hepatitis related deaths (national)
Modelled
HBV
8
2019
(6 - 10)
IHME, GBD 2019 (accessed 2022)
Survey/surveillance
No data available
HBV chart
Modelled
HCV
3
2019
(2 - 5)
IHME, GBD 2019 (accessed 2022)
Survey/surveillance
No data available
HCV chart
Prevalence PWID
No data available
Birth dose vaccination coverage (national)
Survey/surveillance
No data available
Eligible for HBV generic medicines
Eligible for HCV generic medicines
